Short answer: none of the peptides discussed for longevity has controlled human evidence that it slows aging or extends lifespan. NAD+ precursors have the most randomized-trial data, and even those trials mostly show a biomarker rising rather than people aging more slowly. Below are eight compounds people actually search for, ranked by how strong the human evidence is, with what side effects the studies reported and how long researchers waited before measuring anything.
Research-use-only educational overview. This is not medical advice and not a recommendation to use, buy, or take any compound. When people search for the “best peptides for longevity and anti-aging,” they usually mean something more specific than the phrase suggests: which peptides are most studied and most discussed in the context of aging, and what does the evidence actually show? That is the question this page answers. It is worth being blunt up front: “most studied” is not the same as “proven to work,” and neither is the same as “right for you.” Much of the excitement around longevity peptides comes from cell cultures and animal experiments that have never been replicated in rigorous human trials. Sources indexed in PubMed and ClinicalTrials.gov are linked throughout so you can read the primary evidence yourself.
Below we look at eight compounds frequently named in longevity discussions, rank the honesty of the evidence behind each, and link each to its research dosage reference. None of this should be read as an endorsement.
Comparison at a glance
| Peptide | What it’s studied for (longevity/anti-aging) | Evidence tier | Key caveat |
|---|---|---|---|
| Epithalon (AEDG) | Telomerase activation, melatonin/circadian regulation, antioxidant effects | Preclinical (cell/animal) + older, weak human data | No modern controlled human longevity trials |
| MOTS-c | Mitochondrial metabolism, insulin sensitivity, exercise/aging biology | Preclinical only + human observational correlation | No published human efficacy trials |
| NAD+ (and precursors) | Restoring the age-related decline in cellular NAD+ | Early human clinical (RCTs, mostly on oral precursors) | Trials raise NAD+ but rarely change hard outcomes |
| Thymalin | Thymic/immune restoration in older adults | Older human observational + animal data | Methodologically weak; not independently replicated |
| SS-31 (elamipretide) | Protecting mitochondrial function and cardiolipin | Preclinical + human disease trials | Largest phase-3 trial missed its primary endpoints |
| GHK-Cu | Skin remodeling, wound healing, anti-inflammatory and antioxidant signaling | Cell and animal work; human exposure mostly topical | Serum GHK falls with age, but no trial shows raising it extends healthspan |
| Thymosin alpha-1 | Immune restoration; adjuvant to vaccination in older adults | Human randomized trials — but for infection and vaccine response, not aging | Approved in some countries for hepatitis, never for anti-aging |
| Sermorelin / CJC-1295 (GHRH analogs) | Raising the body’s own GH and IGF-1, which decline with age | Small older randomized controlled trials with measured endpoints | Raised IGF-1 and skin thickness; no fat loss, no weight change, no sleep change |
The eight peptides, and what research shows
Epithalon (Epitalon / AEDG)
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on Epithalamin, a pineal-gland extract. In laboratory and animal models it has been reported to activate telomerase, influence melatonin synthesis, and produce antioxidant and geroprotective effects, though a 2025 review notes the mechanisms remain incompletely characterized (Araj et al., 2025). The strongest longevity-specific data are old and preclinical: the parent extract Epithalamin increased mean lifespan in fruit flies, mice, and rats by roughly 11–31% (Anisimov et al., 1998). Human longevity claims trace mainly to older Russian observational work, not modern randomized trials, so the honest tier here is “promising in animals, unproven in people.” See the Epithalon research dosage reference for context on how it is handled in a lab setting.
MOTS-c
MOTS-c is a mitochondrial-derived peptide that acts through the AMPK pathway and whose circulating levels appear to decline with age. In preclinical models it improves glucose metabolism in skeletal muscle and is studied as a regulator of metabolic stress and aging biology (Zheng et al., 2023; Wan et al., 2023). The critical caveat: reviewers themselves note that no effective clinical application has been established and human efficacy trials are lacking. Evidence here is preclinical plus observational human correlation only. Details on the compound are outlined in the MOTS-c research dosage reference.
NAD+ (and its precursors)
NAD+ is a coenzyme central to energy metabolism whose levels fall with age, which is why raising it is one of the most actively tested ideas in the aging field (Campisi et al., 2019). This is the best-studied entry here in humans, but almost all of that data comes from oral precursors rather than injectable NAD+ itself. In a randomized placebo-controlled trial, nicotinamide riboside raised blood NAD+ about 2.6-fold in older adults with mild cognitive impairment and was well tolerated, yet it did not improve cognition (Orr et al., 2023). A separate NMN trial found dose-dependent NAD+ increases that correlated with modest gains in a 6-minute walk test (Kuerec et al., 2024). Bottom line: trials reliably raise the biomarker, but rarely move hard aging outcomes. The NAD+ research dosage reference covers the injectable form.
Thymalin
Thymalin is a thymic peptide preparation studied on the premise that restoring age-related decline in immune (thymic) function could support healthier aging. The most-cited human claim comes from a long-term Russian study in which Thymalin, alone or combined with Epithalamin, was associated with reduced mortality and lower rates of age-related disease in people over 60 (Khavinson & Morozov, 2002). Those results are striking on paper but come from older, methodologically limited work that has not been independently replicated in modern controlled trials, so they should be read with real caution. The Thymalin research dosage reference provides background on the compound.
SS-31 (elamipretide)
SS-31, also called elamipretide, is a mitochondria-targeting peptide that binds cardiolipin on the inner mitochondrial membrane and, in preclinical models, restores mitochondrial bioenergetics relevant to age-related decline (Szeto, 2014). It is the most clinically advanced peptide here, but the human record is sobering: the pivotal phase-3 MMPOWER-3 trial in primary mitochondrial myopathy found that elamipretide did not improve the 6-minute walk test or fatigue versus placebo, though it was well tolerated (Karaa et al., 2023). That is a disease trial rather than a longevity trial, but it is the strongest efficacy signal available, and it was negative on its primary endpoints. See the SS-31 research dosage reference for more.
GHK-Cu (the copper peptide)
GHK is a short peptide that circulates naturally in human serum and binds copper avidly, forming the GHK-Cu complex. Its link to aging is a measured one: average serum levels run about 200 ng/mL at age 20 and fall to roughly 80 ng/mL by age 60 (Dou et al., 2020). In cell and animal work the peptide promotes skin remodeling and wound healing and shows antioxidant and anti-inflammatory activity; the same review reports preliminary observations that GHK partially reversed cognitive impairment in aging mice. That is where the evidence stops. A molecule declining with age is a reason to study it, not proof that restoring it does anything for human healthspan — and the review frames its own findings as a rationale for future preclinical and clinical aging studies, not as a result. Most human exposure to GHK-Cu is topical and cosmetic rather than systemic. See the GHK-Cu research dosage reference for how it is handled in a lab setting.
Thymosin alpha-1
Thymosin alpha-1 is a chemically defined thymic peptide, and it has the cleanest human trial record on this page — but that record is about immunity, not aging. It has been tested as an adjuvant to influenza vaccination in older adults, on the premise that immune senescence blunts vaccine responses; both animal experiments and human trials reported enhanced vaccine responses (Ershler et al., 2007). Note carefully what that does and does not say. Improving an older person’s response to a vaccine is a real, measurable outcome. It is not evidence of slowed aging, longer life, or reversal of age-related decline. Thymosin alpha-1 is approved in a number of countries for hepatitis B and C and as an immune adjuvant; it holds no approval anywhere as an anti-aging therapy. Details are on the Thymosin alpha-1 research dosage reference. Do not confuse it with Thymalin above: Thymosin alpha-1 is one defined molecule, Thymalin is a crude thymus extract.
Sermorelin and CJC-1295 (GHRH analogs)
Growth hormone and IGF-1 fall with age, so prompting the pituitary to release more of your own GH is one of the oldest ideas in anti-aging medicine. It has actually been tested. In a placebo-controlled trial, 19 healthy adults aged 55 to 71 self-injected a GHRH(1-29) analog nightly for 16 weeks. IGF-1 rose about 28%, skin thickness increased in both sexes, and lean body mass increased in men only (Khorram et al., 1997). Just as informative is what did not move: body weight, fat mass, bone mineral density and sleep quality were all unchanged, and every benefit beyond skin thickness appeared in men and not in women. The same cohort also showed measurable immune activation, including more B cells and stronger mitogen responses (Khorram et al., 1997). That is a genuine controlled human result — and it is a modest one, from a 19-person study almost three decades old. For the full week-by-week picture see our review of what sermorelin actually changed in trials, plus the Sermorelin research dosage reference.
What the evidence actually supports
Ranked honestly by strength of human evidence, NAD+ (through oral precursors) sits at the top of this list simply because it has multiple randomized controlled trials, though even those mostly demonstrate a biomarker change rather than a longevity benefit. SS-31 has the most advanced clinical program, but its largest trial failed its primary endpoints. Epithalon and MOTS-c rest largely on animal and cell work, with human longevity claims that are either very old (Epithalon) or essentially absent (MOTS-c). Thymalin’s dramatic mortality figures come from dated, unreplicated research. In short: none of these compounds has robust, modern, controlled human evidence of extending human lifespan or reversing aging. The compounds with genuinely strong human efficacy data in the broader “metabolic aging” conversation, such as GLP-1 receptor agonists for weight and metabolic outcomes, are not on this list precisely because they are a different class with a different, much larger evidence base.
How long did studies wait before measuring anything?
Much of the traffic behind “best peptides for longevity” is really asking about timing. Here is what the published trials used — the only honest answer available.
| Compound | Earliest measured change | Longest published follow-up | What was measured |
|---|---|---|---|
| GHRH analog (sermorelin family) | ~2 weeks (IGF-1) | 16 weeks | IGF-1, skin thickness, lean mass, immune markers |
| NAD+ precursors (NR, NMN) | Weeks (blood NAD+) | Months | Blood NAD+, cognition, 6-minute walk |
| SS-31 (elamipretide) | Weeks | Phase-3 duration | 6-minute walk, fatigue — both negative |
| Thymosin alpha-1 | Weeks after vaccination | One influenza season | Vaccine response in older adults |
| Epithalon, MOTS-c | Not established in humans | Not established | Animal lifespan and metabolic markers only |
Notice the pattern: every entry with a short time-to-change is measuring a biomarker, not aging. No human trial has run long enough to measure the outcome the search phrase implies, so any specific “results timeline” for anti-aging peptides is constructed rather than measured.
Side effects reported in the research
Safety data for this group ranges from thin to absent. What has actually been published:
- GHRH analogs. The 16-week controlled trial reported transient hyperlipidemia that resolved by the end of the study and no other adverse effects among 19 subjects (Khorram et al., 1997). Class-level concerns discussed for GH/IGF-1-axis compounds include fluid retention, joint aches, dysglycemia, and a biologically plausible but unproven concern about chronically raising IGF-1.
- SS-31 (elamipretide). Well tolerated in its phase-3 trial — worth stating plainly, because it was safe and it missed its primary endpoints (Karaa et al., 2023).
- NAD+ precursors. Nicotinamide riboside was well tolerated in a randomized placebo-controlled trial in older adults (Orr et al., 2023).
- Epithalon, MOTS-c, Thymalin. No modern controlled human safety data. The absence of reported side effects here reflects the absence of trials, not a clean safety record.
- Purity and sourcing. Compounds sold as research chemicals are not made to pharmaceutical standards, so contamination and mislabeling are a risk separate from the molecule itself.
Important limitations
- Research-use-only. Every compound discussed here is presented for educational and research context. None is described as a treatment, and nothing here tells you to use, buy, or take any of them.
- Not approved for longevity or anti-aging. None of these peptides is an approved anti-aging therapy. Elamipretide has been studied in specific mitochondrial diseases; the others are largely investigational or sold only as research chemicals.
- Individual results and safety are unknown. Long-term safety data in healthy people are minimal to nonexistent for most of these, and animal or biomarker results do not reliably predict human outcomes.
- Not medical advice. Consult a qualified healthcare professional before making any health decision. If you are exploring the numbers behind published research protocols, a peptide dosage calculator can help you understand reconstitution math in a research context only.
FAQ
Which peptide has the strongest human evidence for aging?
Of the compounds on this page, NAD+ (via oral precursors such as NR and NMN) has the most human randomized-trial data for an aging-related outcome. But even those trials mainly show that NAD+ levels rise, not that aging is slowed or reversed. Human longevity outcomes remain unproven for the whole group.
Do any of these peptides actually extend human lifespan?
No peptide here has been shown to extend human lifespan in controlled trials. Lifespan-extension data exist for the pineal extract Epithalamin in flies, mice, and rats (Anisimov et al., 1998), but animal findings frequently fail to translate to people.
Is “most studied” the same as “best”?
No. “Most studied” or “most discussed” reflects research and marketing attention, not proven benefit or safety. A compound can be widely talked about and still lack the controlled human evidence needed to call it effective, which is exactly the situation for most peptides in longevity conversations.
What are the side effects of longevity peptides?
For most of them nobody knows, because the trials that would find out have not been run. Where data exist: GHRH analogs caused transient hyperlipidemia in one 16-week trial; elamipretide and nicotinamide riboside were both well tolerated in theirs. Epithalon, MOTS-c and Thymalin have no modern human safety data at all, which is not the same as being safe.
How long before longevity peptides show anything?
In published trials, biomarkers such as IGF-1 or blood NAD+ moved within about 2 to 4 weeks, and structural measures such as skin thickness were assessed at 16 weeks. No trial has run long enough to measure aging itself, so any specific timeline for “anti-aging results” is invented rather than measured.
Is GHK-Cu or thymosin alpha-1 the best pick here?
Neither stands out for longevity specifically. Thymosin alpha-1 has the cleanest human trials of anything on this page, but they tested vaccine and infection responses, not aging. GHK-Cu has a well-documented age-related decline in serum levels and good preclinical data, but no human healthspan trial.
